Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Director | June 10, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date June 10, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.95 · Expires 2036-06-10 | Direct | 40,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 40,000 · Balance 40,000 F1: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 30, 2026 22:17 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001140361-26-027004 · form4.xml · derivative · entry 1 Zhang Ping · CIK 0002050176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| May 14, 2026 Filed May 21, 2026 01:03 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Disposition to issuerStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $10.18 | $0.00 |
DisclosureSEC source: 0001140361-26-022303 · form4.xml · derivative · entry 1 Zhang Ping · CIK 0002050176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2035-05-27 F1 · kind: The option was canceled by mutual agreement of the Reporting Person and the Issuer. The Issuer shall provide the Reporting Person with consideration for the cancellation of the option, the form and amount of which shall be determined by the Issuer in its sole discretion; provided that such consideration shall not be economic in value. F1 · price: The option was canceled by mutual agreement of the Reporting Person and the Issuer. The Issuer shall provide the Reporting Person with consideration for the cancellation of the option, the form and amount of which shall be determined by the Issuer in its sole discretion; provided that such consideration shall not be economic in value. F2 · derivative.exercise_date: The canceled option represented a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which would have vested on May 27, 2026, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001140361-26-000832 · form4.xml · derivative · entry 1 Zhang Ping · CIK 0002050176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-07 F1 · derivative.exercise_date: This option represents a right to purchase a total of 100,000 shares of the Issuer's common stock, 25% of which will vest on January 7, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 05, 2025 Filed Aug 8, 2025 00:00 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001140361-25-029693 · form4.xml · derivative · entry 1 Zhang Ping · CIK 0002050176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-08-05 F1 · derivative.exercise_date: This option represents a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which will vest on August 5, 2026, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| May 27, 2025 Filed May 28, 2025 22:13 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $10.18 | $0.00 |
DisclosureSEC source: 0001140361-25-020669 · form4.xml · derivative · entry 1 Zhang Ping · CIK 0002050176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-05-27 F1 · derivative.exercise_date: This option represents a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which will vest on May 27, 2026, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:05 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001140361-25-000426 · form4.xml · derivative · entry 1 Zhang Ping · CIK 0002050176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2035-01-05 F1 · derivative.exercise_date: This option represents a right to purchase a total of 52,000 shares of the Issuer's common stock, which will vest in 36 equal monthly installments through January 5, 2028, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.